Dear Editor,

We read with interest a recent study published in the journal by Ng et al. [1], regarding the positive relationship observed between immune-related adverse events (irAE) and the clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICI). However, irAE can sometimes be lethal and therefore requires a high degree of caution.

The recent updated IMbrave150 trial reported that patients with treatment-related pneumonia accounted for approximately 1% of the patients, including one who died due to an adverse event [2]. ICI-related pneumonia is a rare but potentially life-threatening irAE. Indeed, ICI-related pneumonia is the most common fatal irAE in patients with cancers other than HCC who receive programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors, accounting for 35% of PD-1/PD-L1 inhibitor-related deaths [3]. We herein report 2 fatal cases involving patients treated with atezolizumab plus bevacizumab for HCC. In both patients, ICI-related pneumonia was provisionally the cause of death.

Case 1 was an 85-year-old woman with hepatitis B, who developed HCC 6 years previously. After 5 transcatheter arterial chemoembolization treatments, she was treated by systemic chemotherapy with sorafenib for 5 months and ramucirumab for the subsequent 4 months. Chest CT showed honeycomb lung in the lower lobes before treatment (Fig. 1a). Abdominal CT showed multiple intrahepatic recurrences. Since her liver function was well preserved (Child-Pugh class A), we started to treat the patients with intravenous atezolizumab (1,200 mg) plus bevacizumab (15 mg/kg) every 3 weeks. She complained of grade 1 cough (CTCAE ver 5.0) on day 5 after the start of ICI therapy and was admitted to our hospital on day 18 because of anorexia, malaise, and dyspnea. Chest CT showed bilateral interstitial pneumonia (Fig. 1b). The patient was judged to have grade 3 ICI-related pneumonia because other causes of dyspnea (e.g., respiratory infection and cardiac disease) were denied. Since the patient did not respond to intravenous prednisolone (1 mg/kg) within 48 h, we treated her with steroid pulse therapy (methylprednisolone, 1,000 mg/day) for 3 days, followed by prednisolone (1.5 mg/kg). The serum KL-6 level was 381 U/mL (normal <500 U/mL) before treatment, 421 U/mL at admission, and 1,523 U/mL 7 days after admission. However, she died of respiratory failure on the 29th day after the start of ICI treatment. Autopsy revealed diffuse...
alveolar damage in the upper and middle lobes of both lungs (Fig. 1c) and honeycomb lung in the lower lobe. These findings suggested chronologically different phases of inflammation. Mild infiltration of CD4- and CD8-positive lymphocytes was present, together with prominent PD-L1-positive cells in the mesenchymal tissue of the lung (Fig. 1d).

Case 2 was an 88-year-old woman who developed HCC associated with type C cirrhosis. She underwent laparoscopic hepatic resection of segment 6, 2 radiofrequency ablation treatments, and 2 transcatheter arterial chemoembolization treatments. She had undergone thoracoscopic right lower lobectomy for lung adenocarcinoma 6 years previously without a subsequent recurrence. Abdominal CT showed multiple intrahepatic and extrahepatic recurrences (Fig. 2a). Since her liver function was well preserved (Child-Pugh class A), the patient was treated with atezolizumab (1,200 mg) plus bevacizumab (15 mg/kg) every 3 weeks. After 5 courses of ICI treatment, bevacizumab was discontinued due to grade 3 proteinuria, while atezolizumab was sustained. Abdominal plain CT showed a partial response of the extrahepatic lesions (Fig. 2b). After 11 courses of treatment, however, the patient was hospitalized for dyspnea. Chest CT showed bilateral interstitial pneumonia (Fig. 2c), which was diagnosed as ICI-related pneumonia. The serum KL-6 levels were 360 U/mL before ATZ + BEV administration, 486 U/mL after 10 courses, and 819 U/mL at admission. She did not respond to steroid treatment and died on the 6th day of hospitalization.
Discussion

A recent study on the ICI therapy for lung cancer reported that the presence of pulmonary fibrosis before treatment is a risk factor for the development of ICI-related pneumonia [4]. Moreover, a phase 2 study of atezolizumab for non-small cell lung cancer with pre-existing interstitial pneumonia was terminated early due to the high incidence of ICI-related pneumonia [5]. As was confirmed in those clinical trials, our two cases of ICI-related pneumonia were characterized by a history of lung disease. Indeed, case 1 had preceding interstitial pneumonia and developed ICI-related pneumonia immediately after the start of ICI therapy. Case 1 was treated with ATZ + BEV after consultation with a pulmonologist prior to treatment. The decision was made because the patient did not respond to standard first- and second-line chemotherapy and was determined to have inactive interstitial lung disease based on the absence of respiratory symptoms and elevated KL-6 levels. The concentration of serum KL-6, a known biomarker for interstitial lung disease, was elevated after the onset of ICI-related pneumonia but was not predictive of the onset of ICI-related pneumonia in our cases. Thus, special attention to preceding interstitial lung damage seems inevitable when ICIs have become the choice of treatment, even for HCC patients.

We found that the lung damage in case 1 was characterized by the infiltration of PD-L1-positive cells. This strongly suggests that ICI-related pneumonia is predominantly a consequence of an increased immune response via the breakdown of the PD-1/PD-L1 system. In conclusion, our experiences suggest the need for careful monitoring of ICI-related pneumonia in HCC patients, particularly those with pre-existing lung disease.

Acknowledgments

We would like to thank Koko Motodate for providing excellent secretarial support and Japan Medical Communication for editing the English of this paper.
Conflict of Interest Statement

The authors declare no conflict of interest.

Funding Sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

1. Ng KYY, Tan SH, Tan JJE, Tay DSH, Lee AWX, Ang AJS, et al. Impact of immune-related adverse events on efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma. Liver Cancer. 2022;11(1):9–21.

2. Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022; 76(4):862–73.

3. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–8.

4. Atchley WT, Alvarez C, Saxena-Beem S, Schwartz TA, Ishizawar RC, Patel KP, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six Health Care Centers in North Carolina. Chest. 2021;160(2):731–42.

5. Ikeda S, Kato T, Kenmotsu H, Ogura T, Iwasawa S, Sato Y, et al. A phase 2 study of atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonitis. J Thorac Oncol. 2020;15(12):1935–42.